AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 5.09 |
Market Cap | 221.27M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.05 |
PE Ratio (ttm) | -2.48 |
Forward PE | n/a |
Analyst | Buy |
Ask | 5.98 |
Volume | 624,470 |
Avg. Volume (20D) | 253,440 |
Open | 5.66 |
Previous Close | 5.61 |
Day's Range | 5.05 - 5.66 |
52-Week Range | 3.05 - 9.01 |
Beta | undefined |
About ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease;...
Analyst Forecast
According to 3 analyst ratings, the average rating for ABEO stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 253.63% from the latest price.
Next Earnings Release
Analysts project revenue of $83.33K, reflecting a n/a YoY growth and earnings per share of -0.34, making a -46.88% decrease YoY.
3 months ago · seekingalpha.com
Abeona Therapeutics Targets RDEB Market With Promising Pz-cel TherapyAbeona Therapeutics' Pz-cel, a gene-corrected cell therapy for RDEB, is expected to resubmit its BLA in 2H2024, targeting FDA approval by mid-2025. ABEO's AIM platform uses AAV vectors for targeted ge...